Informed Consent for Blood Transfusion and Blood Component Therapy

Section 1info grid
Section 2list block
Section 3text block
Section 4text block
Section 5list block
Section 6list block
Section 7text block
Section 8text block
Section 9text block
Section 10text block
Section 11text block
Section 12text block
Section 13signature block

Informed Consent for Blood Transfusion and Blood Component Therapy

Patient and Administrative Information

Transfusion Decision

[ ] I consent to receive blood and blood products as medically directed by my clinical team.
[ ] I consent to receive blood products EXCEPT the following: ________________________
[ ] I refuse all blood and blood product transfusions and accept the associated medical risks (see Refusal of Blood Products form).

Nature and Purpose of the Transfusion

Blood transfusion involves the intravenous administration of one or more of the following blood components derived from a donor: (1) Packed red blood cells (PRBCs): for treatment of severe anaemia, symptomatic anaemia despite the patient's cardiovascular reserve, or acute haemorrhage. A single unit raises haemoglobin by approximately 1 g/dL. (2) Platelets: for thrombocytopenia (platelet count below 10,000 per microlitre for prophylaxis, or below 50,000 per microlitre prior to invasive procedures) or platelet dysfunction causing active bleeding. (3) Fresh frozen plasma (FFP): for correction of multiple coagulation factor deficiencies (e.g. warfarin reversal, liver failure coagulopathy, dilutional coagulopathy from massive haemorrhage). (4) Cryoprecipitate: concentrated fibrinogen, von Willebrand factor, and Factor XIII for hypofibrinogenaemia or von Willebrand disease. Each unit of blood undergoes mandatory donor screening for blood-borne pathogens (HIV, hepatitis B, hepatitis C, syphilis, and others), ABO and Rhesus blood group typing, antibody screening, and crossmatching against the recipient's blood to minimize the risk of transfusion incompatibility reactions.

Pre-Transfusion Identity Verification Protocol

A mandatory bedside identity verification is performed before any blood product is administered. The nursing staff and/or physician will verify the patient's full name, date of birth, and hospital identification number against the blood unit label and the electronic crossmatch report. If any discrepancy is identified, the transfusion will not proceed until the discrepancy is resolved with the blood bank. Patients must actively confirm their identity verbally before any blood component is connected to the IV line.

Material Risks and Potential Transfusion Reactions

Febrile non-haemolytic transfusion reaction (FNHTR): the most common reaction, occurring in 1 to 3 percent of red cell transfusions and up to 30 percent of platelet transfusions. Caused by recipient antibodies against donor leukocytes or cytokines in the blood product. Presents as fever, chills, and rigors within 4 hours of starting transfusion. Managed by stopping the transfusion, administering acetaminophen, and restarting slowly if FNHTR is confirmed as the diagnosis.
Allergic transfusion reactions: mild urticaria (hives), itching, or flushing occur in 1 to 3 percent of transfusions. Severe anaphylaxis, particularly in IgA-deficient patients receiving IgA-containing products, occurs in approximately 1 in 20,000 to 1 in 47,000 transfusions. Managed with antihistamines, corticosteroids, and adrenaline (epinephrine) for anaphylaxis.
Acute haemolytic transfusion reaction (AHTR): caused by ABO incompatibility due to clerical error; red cell antibodies destroy the transfused cells, releasing haemoglobin and triggering complement activation, hypotension, renal failure, disseminated intravascular coagulation (DIC), and potentially death. The most serious transfusion-related cause of death; prevented by rigorous patient identification protocols.
Transfusion-Associated Circulatory Overload (TACO): volume overload causing acute pulmonary oedema, hypertension, and respiratory failure, occurring in approximately 1 in 100 transfusions; higher risk in elderly patients and those with pre-existing cardiac or renal impairment. Managed with diuretics and oxygen.
Transfusion-Related Acute Lung Injury (TRALI): non-cardiogenic pulmonary oedema developing within 6 hours of transfusion, caused by donor anti-HLA or anti-granulocyte antibodies. Occurs in approximately 1 in 5,000 to 1 in 10,000 transfusions. Requires respiratory support; mortality approximately 5 to 10 percent.
Bacterial contamination (transfusion-transmitted bacterial infection): platelet concentrates stored at room temperature have the highest risk (estimated 1 in 50,000 platelet transfusions). Presents as rigors, shock, and sepsis during or after transfusion.
Viral disease transmission: despite comprehensive donor screening and nucleic acid testing (NAT), residual risk of viral transmission exists. Current estimated risk per unit: HIV approximately 1 in 1.5 to 4.7 million; Hepatitis C approximately 1 in 1.1 million; Hepatitis B approximately 1 in 290,000. Hepatitis E, West Nile virus, CMV, and Zika virus transmission have also been reported.
Iron overload (transfusion haemosiderosis): patients requiring chronic transfusion (e.g. thalassaemia major, myelodysplastic syndrome) accumulate iron in vital organs (liver, heart, endocrine glands) causing organ dysfunction. Managed with iron chelation therapy.

Alternatives to Allogeneic Transfusion

Autologous blood salvage (intraoperative cell salvage): in elective surgical cases, the patient's own blood shed during surgery is collected, filtered, and reinfused. Eliminates alloimmunization and infection risks but not available in all centres or for all procedures.
Preoperative autologous blood donation: the patient donates their own blood for storage and reuse during planned surgery; limited by timing, patient health constraints, and logistical requirements.
Pharmacological alternatives: erythropoiesis-stimulating agents (EPO) to stimulate red cell production; intravenous iron to optimize haemoglobin before surgery; tranexamic acid to minimize surgical blood loss; fibrin glue for local haemostasis.
No transfusion: acceptable in stable patients with mild to moderate anaemia (haemoglobin 7 to 10 g/dL) who are haemodynamically compensated; carries risk of organ ischaemia in patients with cardiovascular, respiratory, or other comorbidities.

Expected Benefits

The primary expected benefit of blood transfusion therapy is correction of the specific haematological deficit for which it is indicated. Packed red blood cell transfusion is expected to increase haemoglobin and alleviate symptoms of anaemia including fatigue, dyspnoea, and haemodynamic instability. Platelet transfusion aims to prevent or treat bleeding in the context of thrombocytopenia. Fresh frozen plasma and cryoprecipitate aim to correct coagulopathy and control active haemorrhage. In the context of acute haemorrhage, transfusion may be life-saving.

Right to Refuse or Withdraw Consent

You have the right to refuse blood transfusion. If you refuse, your physician will explore all feasible alternatives with you. In life-threatening emergencies where you are unable to consent, transfusion may be administered to preserve life unless a legally valid advance directive or refusal of blood form is on your medical record. If you wish to refuse all blood products under all circumstances, please complete a separate Refusal of Blood Products form.

Questions and Understanding Confirmation

I confirm that I have been informed of the indication for transfusion, the type of blood products to be administered, the pre-transfusion verification protocol, and the associated risks. I understand that I will be monitored during the transfusion and that the infusion will be stopped immediately if a transfusion reaction occurs. All my questions have been answered to my satisfaction.

Language Access and Interpreter Services

If English is not your primary language or if you require assistance communicating, a qualified medical interpreter is available at no cost. Please notify your care team before signing this document.

Copy of Consent Acknowledgment

I acknowledge that I have been offered a signed copy of this informed consent form for my own records.

Patient Acknowledgment

I have been informed of the clinical indication for the transfusion, the nature and composition of the blood product(s) to be given, the transfusion reactions and infectious risks described above, and the available alternatives. I consent to receive blood transfusion(s) as clinically directed based on the selection marked above.

Signatures and Verification

Patient / LAR Signature
Physician Signature
Registered Nurse Witness Signature
Date and Time
Document ID: CC-PENDING
CONSENTCOLLECT